Keywords
Cervical cancer screening
HPV-DNA test
Conventional cytology
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To highlight recent advances in cervical cancer screening methods, with emphasis on cytology and HPV DNA testing. Methods: The following inclusion criteria were defined for the material identified in the search: articles published with content relevant to the study's objectives, using bibliographic databases such as PUBMED (US National Library of Medicine National Institutes of Health), Scielo, BVS (Biblioteca Virtual de Saúde) and Acervo Mais. Studies that did not address cervical cancer screening or were outside the data collection period were excluded from the analysis. Experience reports, case studies, book chapters, and duplicate articles in the databases were discarded. Results: Nine relevant studies were identified that address updates in cervical cancer screening methods, published between 2015 and 2024. These studies present different methodologies, objectives, and results, providing a comprehensive view of advancements in this area. The principal author, year of publication, objectives, methodology, and key findings are detailed organized in a table. Final considerations: The HPV-DNA test is more effective than conventional cytology in cervical cancer screening, allowing for early detection of lesions. The adoption of this test, combined with emerging technologies, represents significant progress in prevention, diagnostic accuracy, management of high-risk lesions and reduction of mortality.
References
ALBULESCU A, et al. Epigenetic approaches for cervical neoplasia screening (Review). Exp Ther Med., 2021; 22(6): 1481.
BRASIL. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Diretrizes brasileiras para o rastreamento do câncer do colo do útero. Coordenação de Prevenção e Vigilância. Divisão de Detecção Precoce e Apoio à Organização de Rede. 2. ed. rev. atual. Rio de Janeiro: INCA; 2016.
CHAN KK-L, et al. Primary HPV testing with cytology versus cytology alone in cervical screening—A prospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer, 2021; 148(10):2377–2387.
COIMBRA PHE, et al. Comparação da eficácia da citologia cervical versus testes de DNA de alto risco para o HPV na detecção precoce de lesões cervicais pré-cancerígenas: Uma Revisão Sistemática. Braz J Implantol Health Sci., 2024; 6(7): 317–325.
DE ARRUDA REINEHR T, CARDOSO PINHEIRO C. Análise de estratégias de rastreamento, diagnóstico e prevenção do câncer do colo do útero: revisão sistemática. Rev Cient Integr., 2023; 6(1): e202324.
DANG L, et al. Evaluation of triage strategies for high-risk human papillomavirus-positive women in cervical cancer screening: A multicenter randomized controlled trial in different resource settings in China. Chin J Cancer Res., 2022; 34(5): 496–509.
FARIA IM, et al. Acuidade da citologia oncótica para o diagnóstico da infecção pelo HPV no colo uterino de mulheres portadoras do HIV. Rev Bras Ginecol Obstet., 2008; 30(9): 437–444.
FERREIRA HNC, et al. Screening and hospitalization of breast and cervical cancer in Brazil from 2010 to 2022: A time-series study. PLoS One, 2023; 18(10): e0278011.
FERREIRA MCM, et al. Detecção precoce e prevenção do câncer do colo do útero: conhecimentos, atitudes e práticas de profissionais da ESF. Ciênc Saúde Coletiva, 2022; 27(6): 2291–2302.
GOMES DS, et al. Fatores que interferem na não adesão de mulheres ao teste de Papanicolau: revisão integrativa. Revista Eletrônica Acervo Saúde, 2021; 13(12): e9278.
KUREBAYASHI JMY, et al. Tracking of cellular atypies of the cervix of women in Primary Care. Rev Bras Enferm., 2020; 73(supl. 6): e20200275.
LIN S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer, 2021; 127(21): 4030–4039.
LINDQUIST S, et al. Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study. Gynecol Oncol., 2024; 191: 45–55.
OMS. World Health Organization (WHO). Global strategy to accelerate the elimination of cervical cancer as a public health problem. Genebra: WHO; 2020.
PARRA MR, et al. Screening virus papiloma humano en cáncer cervicouterino. Rev Hosp Clín Univ Chile, 2021; 32(1): 85–92.
RODRIGUES CF, et al. A detecção de tipos específicos de HPV no rastreamento e manejo do câncer cervical. Revista Eletrônica Acervo Médico, 2024; 24: e14987.
DE SANJOSÉ S, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis., 2007; 7(7): 453–459.
SILVA GG, SOUZA MR. Comparação entre métodos tradicionais e novas abordagens tecnológicas na citologia oncótica. Rev Contemp., 2024; 4(11): e6649.
TEIXEIRA JC, et al. Organization of cervical cancer screening with DNA–HPV testing impact on early–stage cancer detection: a population–based demonstration study in a Brazilian city. Lancet Reg Health Am., 2022; 5: 100084.
TEIXEIRA JC, et al. Cervical Cancer Screening with DNA-HPV Testing and Precancerous Lesions Detection: A Brazilian Population-based Demonstration Study. Rev Bras Ginecol Obstet., 2023; 45(1): 21–30.
THOMSEN LT, et al. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology. Acta Obstet Gynecol Scand., 2021; 100(3): 394–402.
YU K, et al. Automated cervical screening and triage, based on HPV testing and computer-interpreted cytology. JNCI Cancer Spectr., 2018; 2(3): pky029.
ZEFERINO LC, et al. Guidelines for HPV-DNA testing for cervical cancer screening in Brazil. Rev Bras Ginecol Obstet., 2018; 40(6): 360–368.